TWI418566B - 與上皮生長因子受體(egfr)結合之抗原結合分子、編碼該抗原結合分子之載體及其用途 - Google Patents
與上皮生長因子受體(egfr)結合之抗原結合分子、編碼該抗原結合分子之載體及其用途 Download PDFInfo
- Publication number
- TWI418566B TWI418566B TW096129232A TW96129232A TWI418566B TW I418566 B TWI418566 B TW I418566B TW 096129232 A TW096129232 A TW 096129232A TW 96129232 A TW96129232 A TW 96129232A TW I418566 B TWI418566 B TW I418566B
- Authority
- TW
- Taiwan
- Prior art keywords
- seq
- antibody
- binding molecule
- antigen
- egfr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83637106P | 2006-08-09 | 2006-08-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200817436A TW200817436A (en) | 2008-04-16 |
TWI418566B true TWI418566B (zh) | 2013-12-11 |
Family
ID=39033344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW096129232A TWI418566B (zh) | 2006-08-09 | 2007-08-08 | 與上皮生長因子受體(egfr)結合之抗原結合分子、編碼該抗原結合分子之載體及其用途 |
Country Status (20)
Country | Link |
---|---|
US (5) | US7662377B2 (fr) |
EP (2) | EP2057192B1 (fr) |
JP (1) | JP5421105B2 (fr) |
KR (1) | KR101452530B1 (fr) |
CN (1) | CN101535343B (fr) |
AR (1) | AR062223A1 (fr) |
AU (1) | AU2007282923B2 (fr) |
BR (1) | BRPI0716639B8 (fr) |
CA (1) | CA2660584C (fr) |
CL (1) | CL2007002318A1 (fr) |
ES (2) | ES2424388T3 (fr) |
HK (1) | HK1131163A1 (fr) |
IL (1) | IL196732A0 (fr) |
MX (1) | MX2009001382A (fr) |
NO (1) | NO20090406L (fr) |
PE (2) | PE20120306A1 (fr) |
RU (1) | RU2457219C2 (fr) |
TW (1) | TWI418566B (fr) |
WO (1) | WO2008017963A2 (fr) |
ZA (1) | ZA200901590B (fr) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4334141B2 (ja) * | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
HUP0700103A3 (en) | 2001-08-03 | 2012-09-28 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
LT1871805T (lt) * | 2005-02-07 | 2019-12-10 | Roche Glycart Ag | Antigeną surišančios molekulės, kurios suriša egfr, jas koduojantys vektoriai ir jų panaudojimas |
AR062223A1 (es) | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
CN106519025B (zh) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
SI2275443T1 (sl) | 2008-04-11 | 2016-03-31 | Chugai Seiyaku Kabushiki Kaisha | Antigen-vezavna molekula, ki se je sposobna ponovljivo vezati na dve ali več antigenskih molekul |
KR20110128320A (ko) | 2009-03-31 | 2011-11-29 | 로슈 글리카트 아게 | 인간화 항-egfr igg1 항체 및 이리노테칸으로의 암 치료 |
JP5501439B2 (ja) | 2009-04-02 | 2014-05-21 | ロシュ グリクアート アクチェンゲゼルシャフト | 完全長抗体と単鎖Fabフラグメントとを含む多重特異的抗体 |
WO2010112194A1 (fr) * | 2009-04-02 | 2010-10-07 | F. Hoffmann-La Roche Ag | Polypeptides se liant à un antigène et anticorps multispécifiques les renfermant |
SG175077A1 (en) | 2009-04-07 | 2011-11-28 | Roche Glycart Ag | Trivalent, bispecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
MX2012003396A (es) | 2009-09-16 | 2012-04-10 | Genentech Inc | Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos. |
PE20121363A1 (es) | 2009-10-30 | 2012-10-15 | Janssen Biotech Inc | Antagonistas de il-17a |
RU2012131099A (ru) | 2009-12-29 | 2014-02-10 | Ф. Хоффманн-Ля Рош Аг | Препарат антитела |
US20110200595A1 (en) * | 2010-02-18 | 2011-08-18 | Roche Glycart | TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR |
KR101555740B1 (ko) | 2010-03-10 | 2015-09-25 | 에프. 호프만-라 로슈 아게 | 면역글로불린 용액 정제 방법 |
AR080793A1 (es) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | Anticuerpos biespecificos |
US9149542B2 (en) * | 2010-07-01 | 2015-10-06 | Aeon Medix Inc. | Microvesicles derived from cell protoplast and use thereof |
JP5758004B2 (ja) | 2010-08-24 | 2015-08-05 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ジスルフィドによって安定化されたFv断片を含む二重特異性抗体 |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
EP2617435A4 (fr) * | 2010-09-16 | 2014-03-12 | Univ Osaka | Agents thérapeutiques et agents prophylactiques destinés aux symptômes associés aux maladies auto-immunes, aux maladies inflammatoires, aux maladies allergiques et aux greffes d'organes |
CN108715614A (zh) | 2010-11-30 | 2018-10-30 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
WO2012085111A1 (fr) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Complexe polypeptide-polynucléotide et son utilisation dans l'administration d'une fraction effectrice ciblée |
DK3489255T3 (da) | 2011-02-10 | 2021-08-23 | Roche Glycart Ag | Muterede interleukin-2-polypeptider |
EP2672999A2 (fr) | 2011-02-10 | 2013-12-18 | Roche Glycart AG | Immunothérapie améliorée |
WO2012116927A1 (fr) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Protéines monovalentes de liaison à l'antigène |
ES2549638T3 (es) | 2011-02-28 | 2015-10-30 | F. Hoffmann-La Roche Ag | Proteínas de unión a antígeno |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
WO2013113641A1 (fr) | 2012-01-31 | 2013-08-08 | Roche Glycart Ag | Utilisation de nkp46 en tant que biomarqueur de prédiction pour le traitement du cancer par des anticorps à adcc améliorée |
WO2013119966A2 (fr) | 2012-02-10 | 2013-08-15 | Genentech, Inc. | Anticorps et autres hétéromultimères monocaténaires |
BR112014018374A8 (pt) | 2012-03-02 | 2017-07-11 | Roche Glycart Ag | Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica |
JP6309002B2 (ja) | 2012-06-27 | 2018-04-11 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 標的に特異的に結合する少なくとも1つの結合実体を含む抗体Fc領域結合体を作製するための方法およびその使用 |
EP2867253B1 (fr) | 2012-06-27 | 2016-09-14 | F. Hoffmann-La Roche AG | Méthode de sélection et de production d'entités de ciblage personnalisées fortement sélectives et multi-spécifiques renfermant au moins deux entités de liaison différentes et leurs utilisations |
MX365382B (es) | 2012-08-07 | 2019-05-31 | Roche Glycart Ag | Una combinación de inmunoconjugado y anticuerpo para usarse en el tratamiento de cáncer. |
EP3597747B1 (fr) | 2012-08-24 | 2023-03-15 | Chugai Seiyaku Kabushiki Kaisha | Anticorps fc spécifiques fcgammarii de souris |
WO2014114595A1 (fr) | 2013-01-23 | 2014-07-31 | Roche Glycart Ag | Biomarqueur prédictif pour traitement anticancéreux au moyen d'anticorps à activité adcc accrue |
US10414820B2 (en) * | 2013-03-13 | 2019-09-17 | Imaginab, Inc. | Antigen binding constructs to CD8 |
WO2014163101A1 (fr) | 2013-04-02 | 2014-10-09 | 中外製薬株式会社 | Variant de région fc |
LT3708583T (lt) | 2013-08-01 | 2022-04-11 | Five Prime Therapeutics, Inc. | Afukozilinti anti-fgfr2iiib antikūnai |
MX2016003593A (es) | 2013-10-11 | 2016-06-02 | Hoffmann La Roche | Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico. |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US10329348B2 (en) | 2014-10-23 | 2019-06-25 | Innate Pharma | Treatment of cancers using anti-NKG2A agents |
PL3227332T3 (pl) | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Wielospecyficzne przeciwciała |
KR20180054923A (ko) | 2014-12-19 | 2018-05-24 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
US9969800B2 (en) | 2015-02-05 | 2018-05-15 | Chugai Seiyaku Kabushiki Kaisha | IL-8 antibodies |
CA2994951A1 (fr) | 2015-08-07 | 2017-02-16 | Imaginab, Inc. | Constructions de liaison d'antigene se liant a des molecules cibles |
TWI791422B (zh) | 2015-11-23 | 2023-02-11 | 美商戊瑞治療有限公司 | 用於癌症治療之單獨fgfr2抑制劑或與免疫刺激劑組合 |
JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
TWI693940B (zh) | 2016-08-05 | 2020-05-21 | 日商中外製藥股份有限公司 | Il-8相關疾病之治療用或預防用組成物 |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
SG10202112636SA (en) | 2017-05-16 | 2021-12-30 | Five Prime Therapeutics Inc | Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment |
CN109912716B (zh) * | 2017-12-13 | 2022-08-23 | 凯惠科技发展(上海)有限公司 | 一种egfr抗体及其制备方法和应用 |
US11891432B2 (en) | 2018-03-15 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use |
WO2020136147A1 (fr) | 2018-12-26 | 2020-07-02 | Innate Pharma | Composés et méthodes de traitement du cancer de la tête et du cou |
CN110305961B (zh) * | 2019-07-16 | 2023-06-30 | 南方医科大学深圳医院 | miR-1207及其靶基因在检测喉鳞癌中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6407213B1 (en) * | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
WO2005056606A2 (fr) * | 2003-12-03 | 2005-06-23 | Xencor, Inc | Proteines optimisees qui ciblent le recepteur du facteur de croissance epidermique |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1132140A (en) | 1912-06-01 | 1915-03-16 | Williams Sealing Corp | Bottle and cap-fastener. |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0173494A3 (fr) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Récepteurs chimériques par liaison et expression de l'ADN |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
CA2082160C (fr) | 1991-03-06 | 2003-05-06 | Mary M. Bendig | Anticorps monoclonaux humanises et chimeriques |
GB9401182D0 (en) * | 1994-01-21 | 1994-03-16 | Inst Of Cancer The Research | Antibodies to EGF receptor and their antitumour effect |
EP2275119B1 (fr) | 1995-07-27 | 2013-09-25 | Genentech, Inc. | Formulation de protéine stabile, lyophilisée et isotonique |
US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6322980B1 (en) | 1999-04-30 | 2001-11-27 | Aclara Biosciences, Inc. | Single nucleotide detection using degradation of a fluorescent sequence |
EP2275541B1 (fr) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Procédé de contrôle de l'activité d'une molécule fonctionnelle immunologiquement |
US6342221B1 (en) * | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody conjugate compositions for selectively inhibiting VEGF |
AU8822601A (en) | 2000-07-31 | 2002-02-13 | Biolex Inc | Expression of biologically active polypeptides in duckweed |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
WO2002034790A1 (fr) | 2000-10-20 | 2002-05-02 | Idec Pharmaceuticals Corporation | Igg3 rituxan r variant et utilisations therapeutiques |
WO2002100348A2 (fr) * | 2001-06-13 | 2002-12-19 | Genmab A/S | Anticorps monoclonaux humains diriges contre le recepteur de facteur de croissance epidermique (egfr) |
US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
HUP0700103A3 (en) | 2001-08-03 | 2012-09-28 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
US7084257B2 (en) * | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
CA2471551C (fr) | 2001-12-27 | 2014-09-30 | Glycofi, Inc. | Procede d'ingenierie de structures de carbohydrates de type mammalien |
US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7897842B2 (en) | 2002-03-19 | 2011-03-01 | Plant Research International B.V. | GnTIII expression in plants |
KR100708398B1 (ko) | 2002-03-22 | 2007-04-18 | (주) 에이프로젠 | 인간화 항체 및 이의 제조방법 |
US20030190689A1 (en) | 2002-04-05 | 2003-10-09 | Cell Signaling Technology,Inc. | Molecular profiling of disease and therapeutic response using phospho-specific antibodies |
EP1498491A4 (fr) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc gamma iiia |
CA2481925A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Agent therapeutique pour les patients atteints du fc.gamma.riiia humain |
CA2481656A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cellules dans lesquelles l'activite de la proteine impliquee dans le transport du gdp-fucose est reduite ou perdue |
WO2003085118A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production de composition anticorps |
PL373256A1 (en) | 2002-04-09 | 2005-08-22 | Kyowa Hakko Kogyo Co, Ltd. | Cells with modified genome |
WO2004000102A2 (fr) | 2002-06-19 | 2003-12-31 | Abgenix, Inc. | Procede servant a predire une reponse a une therapie dirigee vers le recepteur du facteur de croissance epidermique |
AU2003270152A1 (en) | 2002-09-12 | 2004-04-30 | Greenovation Biotech Gmbh | Protein production method |
RU2390527C2 (ru) * | 2002-09-27 | 2010-05-27 | Ксенкор, Инк. | АНТИТЕЛО, СОДЕРЖАЩЕЕ Fc-ВАРИАНТНУЮ ЧАСТЬ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АНТИТЕЛО, И СПОСОБ ЛЕЧЕНИЯ МЛЕКОПИТАЮЩЕГО |
CA2549932C (fr) | 2002-12-20 | 2013-08-20 | Greenovation Biotech Gmbh | Ameliorations apportees ou associees a la production de proteines |
CA2512729C (fr) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes |
ES2574993T3 (es) * | 2003-01-22 | 2016-06-23 | Roche Glycart Ag | Construcciones de fusión y uso de las mismas para producir anticuerpos con mayor afinidad de unión al receptor de Fc y función efectora |
MXPA06004836A (es) | 2003-11-05 | 2006-07-06 | Glycart Biotechnology Ag | Anticuerpos cd20 con funcion del efector y afinidad de enlace al receptor fc mejoradas. |
AU2004297616B2 (en) | 2003-12-04 | 2008-12-18 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
CA2577370A1 (fr) * | 2004-08-16 | 2006-03-02 | Medimmune, Inc. | Antagonistes de l'integrine possedant une action cytotoxique a mediation cellulaire dependante de l'anticorps amelioree |
LT1871805T (lt) | 2005-02-07 | 2019-12-10 | Roche Glycart Ag | Antigeną surišančios molekulės, kurios suriša egfr, jas koduojantys vektoriai ir jų panaudojimas |
TWI615407B (zh) * | 2005-08-26 | 2018-02-21 | 羅齊克雷雅公司 | 具有經改變細胞傳訊活性之改質抗原結合分子 |
AR062223A1 (es) * | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
CN102164960A (zh) | 2008-09-26 | 2011-08-24 | 罗氏格黎卡特股份公司 | 双特异性抗-egfr/抗-igf-1r抗体 |
-
2007
- 2007-08-06 AR ARP070103463A patent/AR062223A1/es not_active Application Discontinuation
- 2007-08-08 PE PE2011001531A patent/PE20120306A1/es not_active Application Discontinuation
- 2007-08-08 TW TW096129232A patent/TWI418566B/zh not_active IP Right Cessation
- 2007-08-08 CL CL200702318A patent/CL2007002318A1/es unknown
- 2007-08-08 PE PE2007001057A patent/PE20081132A1/es not_active Application Discontinuation
- 2007-08-09 CN CN200780037124.5A patent/CN101535343B/zh active Active
- 2007-08-09 EP EP07825698.9A patent/EP2057192B1/fr active Active
- 2007-08-09 JP JP2009523372A patent/JP5421105B2/ja active Active
- 2007-08-09 ES ES07825698T patent/ES2424388T3/es active Active
- 2007-08-09 RU RU2009107895/10A patent/RU2457219C2/ru active
- 2007-08-09 EP EP11193812.2A patent/EP2444422B1/fr active Active
- 2007-08-09 US US11/889,215 patent/US7662377B2/en active Active
- 2007-08-09 ES ES11193812.2T patent/ES2576137T3/es active Active
- 2007-08-09 CA CA2660584A patent/CA2660584C/fr active Active
- 2007-08-09 KR KR1020097004840A patent/KR101452530B1/ko active IP Right Grant
- 2007-08-09 BR BRPI0716639A patent/BRPI0716639B8/pt active IP Right Grant
- 2007-08-09 MX MX2009001382A patent/MX2009001382A/es active IP Right Grant
- 2007-08-09 WO PCT/IB2007/003542 patent/WO2008017963A2/fr active Application Filing
- 2007-08-09 AU AU2007282923A patent/AU2007282923B2/en not_active Ceased
- 2007-08-17 US US11/892,010 patent/US7727741B2/en active Active
-
2009
- 2009-01-26 IL IL196732A patent/IL196732A0/en unknown
- 2009-01-28 NO NO20090406A patent/NO20090406L/no not_active Application Discontinuation
- 2009-03-05 ZA ZA2009/01590A patent/ZA200901590B/en unknown
- 2009-11-12 HK HK09110543.2A patent/HK1131163A1/xx unknown
-
2010
- 2010-03-15 US US12/724,386 patent/US8088380B2/en active Active
-
2011
- 2011-11-30 US US13/308,334 patent/US8273328B2/en active Active
-
2012
- 2012-08-17 US US13/588,269 patent/US9074008B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6407213B1 (en) * | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
WO2005056606A2 (fr) * | 2003-12-03 | 2005-06-23 | Xencor, Inc | Proteines optimisees qui ciblent le recepteur du facteur de croissance epidermique |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI418566B (zh) | 與上皮生長因子受體(egfr)結合之抗原結合分子、編碼該抗原結合分子之載體及其用途 | |
JP5763695B2 (ja) | Egfrを結合する抗原結合分子、それをコードするベクターおよびその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |